PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Both yoy net incomes decline, with TRAW at -34.15%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
22.78%
Some D&A expansion while TRAW is negative at -25.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth of 128.24% while TRAW is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
-92.68%
Negative yoy working capital usage while TRAW is 373.56%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
Lower AP growth vs. TRAW's 736.13%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
26.98%
Lower 'other working capital' growth vs. TRAW's 237.46%. David Dodd would see fewer unexpected short-term demands on cash.
-101.99%
Both negative yoy, with TRAW at -220.87%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-120.47%
Negative yoy CFO while TRAW is 7.45%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
72.96%
CapEx growth of 72.96% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
We expand invests by 72.96% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
86.96%
Debt repayment growth of 86.96% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-90.54%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.